New MRI technique to assess brain tumors after treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop and test a novel magnetic resonance imaging (MRI) technique designed to differentiate between tumor growth due to cancer progression and growth resulting from treatment effects in patients with brain tumors. Participants include both healthy volunteers and patients with untreated brain metastases who are scheduled for stereotactic radiosurgery (SRS). The study will utilize a specific MRI intervention known as CEST-MRF to gather data on brain tumor changes post-treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Healthy volunteers \[for Study Aim 1 (SA1) and Study Aim 2 (SA2)\] will be entered into the study if they meet the following criteria:

* Age ≥ 18 years
* Able to understand and give informed consent
* No known cancer diagnosis

Patients \[for Study Aim 1 (SA1)\] will be entered into the study if they meet the following criteria:

* Age ≥ 18 years
* Able to understand and give informed consent
* At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist)

Patients \[for Study Aim 3 (SA3)\] will be entered into the study if they meet the following criteria:

* Age ≥ 18 years
* Able to understand and give informed consent
* At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist)
* Planned SRS treatment

Exclusion Criteria:

Healthy volunteers (SA1 \& SA2) and patients (SA1 \& SA3) exclusion criteria:

* Pregnant or breastfeeding women
* Pre-existing medical conditions, including the likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest
* Age \< 18 years

Where it's running

• Memorial Sloan Kettering Cancer Center (All Protocol Activities)
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Ouri Cohen, PhD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Ouri Cohen, PhD
• Email: coheno1@mskcc.org
• Phone: 646-608-8259

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using ex vivo pharmacoscopy to guide treatment for brain metastases

  This project will test whether pharmacoscopy, a lab test that screens a patient's tumor cells against many drugs, can help pick effective treatments for adults having surgery for brain metastases.

  Recruiting at 2 sites Phase 2 University of Zurich · Basel and 2 other locations · NCT06620380

• Evaluating brain metastasis treatment using PET imaging

  This study is testing if a special type of brain scan can help doctors see how well treatment is working for patients with brain tumors caused by cancer.

  Recruiting Phase 1 Baptist Health South Florida · Miami, Florida · NCT06048094

• Stereotactic radiosurgery for lung cancer that has spread to the brain

  This study is testing if a targeted radiation treatment can help people with small cell lung cancer that has spread to their brain feel better and improve their outcomes.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05419076

• Using 18F-Fluciclovine to Monitor Brain Metastases After Radiation Therapy

  This study is testing a new imaging agent called 18F-fluciclovine to see if it can help track how well radiation therapy is working for people with large brain metastases.

  Recruiting Phase 1 Baptist Health South Florida · Miami, Florida · NCT04689048

• Belvarafenib in BRAF-altered brain tumors

  This Phase 2 study tests Belvarafenib daily to see if it can help people with BRAF-altered primary or metastatic brain tumors.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07688356

• EarlyFDG PET after Radiotherapy to See Brain Metastases and Radionecrosis

  This study tests whether a short FDG-PET scan after radiotherapy can help tell apart radionecrosis from recurring brain metastases in adults.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT07632092

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.